These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3581101)

  • 1. Phase II study of mitoxantrone in epithelial ovarian cancer.
    Lawton F; Blackledge G; Mould J; Latief T; Watson R; Chetiyawardana AD
    Cancer Treat Rep; 1987 Jun; 71(6):627-9. PubMed ID: 3581101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
    Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
    Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
    Foss-Abrahamsen A; Lenner P; Hedenus M; Landys K; Noppa H
    Cancer Treat Rep; 1987 Dec; 71(12):1209-12. PubMed ID: 3690531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.
    Nicoletto MO; Artioli G; Donach M; Sileni VC; Monfardini S; Talamini R; Veronesi A; Ferrazzi E; Tumolo S; Visonà E; Amichetti M; Endrizzi L; Salvagno L; Prosperi A; Azzoni P
    Gynecol Oncol; 2001 Feb; 80(2):221-6. PubMed ID: 11161863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Tarraza HM; Boyce CR; Smith WG; Jones MA
    Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
    Markman M; Hakes T; Reichman B; Rubin S; Curtin J; Barakat R; Jones W; Lewis JL; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 May; 49(2):185-9. PubMed ID: 8504986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
    Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
    Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital.
    Tepmongkol P; Suphaphongs N; Thansakul A; Jirapanuwat S; Skulchan V; Rojananin S; Chantarakul N
    J Med Assoc Thai; 1989 Feb; 72(2):82-9. PubMed ID: 2738491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone in elderly women with advanced breast cancer: a phase II study.
    Repetto L; Simoni C; Venturino A; Biancardi V; Gasco M; Campora E; Rosso R
    Anticancer Res; 1995; 15(5B):2297-300. PubMed ID: 8572641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
    Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
    Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.